| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
David Schaffer last filed a Form 4 in October 2021, as Director at FDMT. The filings on record cover 2 companies. David Schaffer's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, David Schaffer's trades have earned a strong insider score of 86/100 across 7 rated trades. Over a 12-month horizon, all 7 of those trades were profitable, with an average 12-month return of +74.1%.
At the last filing, the largest reported position was 901,215 shares of FDMT. The FDMT filings lean toward selling, a net 98,785 shares.
David Schaffer has 11 Form 4 filings on record from January 2017 to October 2021, across 2 companies: Director at 4D Molecular Therapeutics (FDMT), 2021; Director at uniQure (QURE), 2017–2020.
The 26 reported transactions were 17 open-market sales, 6 option or other derivative awards and 3 stock awards.
Counted by filing, the open-market trades come to no purchases and 7 sales worth about $3.4M.
The largest open-market sale was 36,285 shares of FDMT at an average $31.36 on October 22, 2021, about $1.1M. Twelve months later FDMT was down 79%.
Shares as reported in the last Form 4 for each company; the most recent is from October 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 22, 2021 | FDMT 4d Molecular Therapeutics, Inc. | Director | Sell | 36,285 | $31.36 | $1,137,819.21 | -3.9% | -53.9% | -78.9% | |
| Sep 30, 2021 | FDMT 4d Molecular Therapeutics, Inc. | Director | Sell | 29,256 | $27.89 | $815,863.26 | -3.0% | -21.6% | -70.2% | |
| Sep 28, 2021 | FDMT 4d Molecular Therapeutics, Inc. | Director | Sell | 33,244 | $31.90 | $1,060,518.15 | -3.3% | -28.2% | -70.5% | |
| Jan 28, 2020 | QURE Uniqure N.V. | Director | Sell | 806 | $62.27 | $50,189.62 | -1.8% | - | - | |
| Jan 28, 2019 | QURE Uniqure N.V. | Director | Sell | 1,210 | $31.31 | $37,885.10 | -2.6% | - | - | |
| Jan 17, 2019 | QURE Uniqure N.V. | Director | Sell | 7,500 | $30.71 | $230,325.00 | -14.6% | - | - | |
| Jan 29, 2018 | QURE Uniqure N.V. | Director | Sell | 2,878 | $18.53 | $53,329.34 | -15.8% | - | - |